Heterocyclic Building Blocks-piperidine

34622-39-4, (S)-2-Piperidinone-6-carboxylic acid is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 7-5: Preparation of (S)-N-(4-methoxybenzyl)-6-oxo-N-(4-(trimethylsilyl)but-2-en-1-yl)piperidine-2-carboxamide I5.1 and (S)-tert-butyl 2-((4-methoxybenzyl)(4-(trimethylsilyl)but-2-en-1-yl)carbamoyl)-6-oxopiperidine-1-carboxylate 15.2 [0199] [0200] To a solution of (S)-6-oxopiperidine-2-carboxylic acid (1.74 g, 12.15 mmol) in DMF (120 mL) were added N-(4-methoxybenzyl)-4-(trimethylsilyl)but-2-en-1-amine 14 (3.20 g, 12.2 mmol), EDC (2.79 g, 14.6 mmol) and HOBt (2.23 g, 14.6 mmol). After 2h stirring at room temperature EtO2 (300 mL) was added to the reaction and washed with sat. aq. NaCl solution (3 ¡Á 75 mL). The organic layer was dried over MgSO4 and the solvent was removed under reduced pressure and the crude compound I5.1 was used for the next step without further purification. MS (ESI): m/z (percent) = 389.29 [M + H]+, 777.25 [2M + H]+, 34622-39-4

As the paragraph descriping shows that 34622-39-4 is playing an increasingly important role.

Reference£º
Patent; Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.; The designation of the inventor has not yet been filed; EP2899192; (2015); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.28697-07-6,N-Cbz-2-Piperidinecarboxylic acid,as a common compound, the synthetic route is as follows.

Example 27N-(3,5-Dichloroisonicotinoyl)-4-(2-piperidin-2-yl-3H-imidazo[4,5-b]pyridin-3-yl)-L- phenylalanine (Compound 11) To Intermediate 2 (3.41g) in DCM (40ml) is added 1-Cbz-2-piperidinecarboxylic acid (4.48g), HOBt (346mg) and EDC (4.88g). The reaction is stirred at room temperature for 3 days. The reaction is partitioned between DCM (40ml) and water (40ml) and the organic layer washed with 10% AcOH solution (40ml). The solvent is removed in vacuo and the residue dissolved in AcOH (12ml) and heated in a microwave at 1200C for 10 minutes. The mixture is evaporated to dryness in vacuo and partitioned between EtOAc (40ml) and saturated NaHCO3 (40ml), the organic layer is dried over Na2SO4, filtered, evaporated to dryness and the residue purified by chromatography on silica eluting with EtOAc/heptane. To a portion of the purified material (1.25g) in DCM (20ml) is added TFA (1.51 ml) at room temperature. The reaction is stirred at room temperature for 20 hours. The reaction is partitioned between DCM (50ml) and saturated NaHCO3 (50ml), dried over Na2SO4, filtered and the evaporated to dryness. To a portion of the obtained material (348mg) in DCM (4ml) is added DIPEA (138mul) followed by 2,6-dichloroisonicotinoyl chloride (169mg) in DCM (2ml). The reaction is stirred at room temperature for 1 hour. The reaction is partitioned between DCM (40ml) and water (40ml). The organic layer is dried over Na2SO4, filtered and evaporated to dryness in vacuo and the residue purified by chromatography on silica eluting with EtOAc/heptane. To the purified material (310mg) in EtOH (10ml) under N2(g) is added 10% Pd on carbon (50mg). The mixture is flushed with H2(g) and stirred at atmospheric pressure for 3 days. The mixture is filtered through a pad of celite, and the filtrate evaporated to dryness in vacuo. The crude material is dissolved in THF (4ml) and added slowly over 1 hour to a stirred solution of NaOH (2.0M, 5ml). Once addition is complete the reaction is stirred at room temperature for 1 hour, the reaction mixture acidified to acidic pH with HCI (6.0M), concentrated in vacuo and purified by preparative HPLC (Method C) to afford the title compound as a white solid (61 mg, 1%). LCMS (Method A) 539 [M+H] RT 1.72 mins. 1H NMR 300MHz (CDCI3) .81.10-1.41 (m, 2H), 1.43-1.60 (m, 2H), 1.70 (m, 2H), 1.88 (d, 1 H), 2.41 (m, 1 H), 3.00 (m, 2H), 3.39 (d, 1 H), 3.75 (d, 1 H), 4.77 (m, 1 H), 7.25 (m, 3H), 7.50 (d, 2H), 8.00 (d, 1 H), 8.09 (dd, 1 H), 8.40 (s, 2H), 28697-07-6

The synthetic route of 28697-07-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; UCB PHARMA, S.A.; WO2008/64823; (2008); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.158407-04-6,tert-Butyl 4-(bromomethyl)piperidine-1-carboxylate,as a common compound, the synthetic route is as follows.

Step B: tert-Butyl 4-{[(5-cyanopyridin-2-yl)sulfanyllmethyl|piperidine-l-carboxylate 6-Sulfanylpyridine-3-carbonitrile (220 mg, 1.6 mmol) was dissolved in DMF (10 mL) in a round bottom flask at room temperature, tert-butyl 4-(bromomethyl) piperidine-l-carboxylate (530 mg, 1.9 mmol) was added, followed by potassium carbonate (440 mg, 3.2 mmol). The resulting mixture was heated to 80 C and stirred over night. The reaction mixture was diluted with EtOAc, washed with water and brine, then dried over anhydrous sodium sulfate, filtered and concentrated. The resulting residue was purified by MPLC (eluent: 0->100% EtOAc/Hexane gradient) to provide tert-Butyl 4-{[(5-cyanopyridin-2-yl)sulfanyl]methyl}piperidine-l- carboxylate. NMR delta (ppm)(500 Hz, CDCh): 8.64 (d, J= 2.1 Hz, 1H), 7.64 (dd, J= 8.4, 2.2 Hz, 1H), 4.11 (m, 2 H), 3.17 (d, J= 6.8 Hz, 2H), 2.68 (m, 2 H), 1.84-1.80 (m, 2 H), 1.80-1.72 (m, 1 H), 1.55 (s, 9 H), 1.28-1.16 (m, 2 H). LC-MS (IE, m/z): 356 [M + 23]+.

158407-04-6, The synthetic route of 158407-04-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MERCK SHARP & DOHME CORP.; WALSH, Shawn; PASTERNAK, Alexander; CATO, Brian; FINKE, Paul, E.; FRIE, Jessica; FU, Qinghong; KIM, Dooseop; PIO, Barbara; SHAHRIPOUR, Aurash; SHI, Zhi-Cai; TANG, Haifeng; WO2013/39802; (2013); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.503614-92-4,1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid,as a common compound, the synthetic route is as follows.,503614-92-4

General procedure: A solution of 5,6-dihydro-3- (4-morpholinyl) -1- [4- (2-oxo-1-piperidinyl) phenyl]2 (1H) -pyridone and ethyl [(4-methoxyphenyl) hydrazino] chloroacetate,In the triethylamine for the acid binding agent under the conditions of condensation, and then by hydrochloric acid deprotection,The resulting intermediates,In the ethylene glycol under high temperature conditions with ammonia reaction in the preparation of an average of apixaban, the purity of 95.4%.In the 50L reactor,Add 2 kg of apixaban crude (purity 95. 4%) and 16L with 10% ammonia in ethylene glycol solution, heated to 90 C dissolved, then add 16L water cooling, stirring at 40 ~ 50 C for 2 hours , Cooling to 0 ~ 10 C. And then filtered to dryness to give 8 kg of a white solid, 90% yield, and an HPLC purity of 99. 97%.

503614-92-4 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid 22240440, apiperidines compound, is more and more widely used in various fields.

Reference£º
Patent; Zhongmei HuashitongBiotechnology Pharmaceutical Technology (Wuhan) Co.,Ltd; HU, MINGLONG; WU, HAOHAO; CUI, JIAN; QIAN, LINA; (13 pag.)CN106188036; (2016); A;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

4897-50-1, 4-Piperidinopiperidine is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 1.; Preparation of 1-chlorocarbonyl-4-piperidinopiperidine base (IRT-4):; Dissolving 4-piperdinoperidine (100g) in benzene (1580ml) under stirring for 15 to 30 minutes at room temperature, adding a solution of triphosgene (150g) in benzene (660 ml) over a period of 1 to 3 hours at a temperature of 20¡ã- 25¡ãC. Filtering the solid, washing it with benzene and drying, then dissolve the dried solid in chloroform (5900 ml) by stirring at room temperature for about 30 minutes. Charging aqueous sodium bicarbonate solution (400 ml), stirring and separating chloroform layer, washing the chloroform layer with water (1800 ml), separating chloroform layer anddistilling off chloroform under vacuum at a temperature up to below 45¡ãC to obtain 1-chlorocorbonyl-4-piperidopiperidine base (60 g).

4897-50-1, The synthetic route of 4897-50-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SHILPA MEDICARE LIMITED; WO2006/16203; (2006); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

22990-34-7, 2-(4-Piperidyl)-2-propanol is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(1) 2-Chloro-3-methyl-5-nitropyridine (6.02g) in N, N- dimethylformamide (35) at room temperature was added 2- (4-piperidinyl) -2-propanol (5.0 g) and potassium carbonate (9.65g), and stirred for 6 hours at 80 . After the reaction, it cooled to room temperature and, after addition of water, to give a yellow solid (9.09g) collected by the precipitated solid filtered.

22990-34-7, As the paragraph descriping shows that 22990-34-7 is playing an increasingly important role.

Reference£º
Patent; Mitsubishi Tanabe Pharma Corporation; Watanabe, Masayuki; Furukawa, Hiroyuki; Hamada, Maiko; Fuji, Naoto; Ushio, Hiroyuki; Takashima, Toru; (81 pag.)KR2015/2661; (2015); A;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

41373-39-1, (S)-Piperidin-2-ylmethanol is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Into a 50-mL round-bottom flask, was placed a solution of 2-methylpyridine-4-carboxylic acid (548 mg, 4.00 mmol, 1.00 equiv), (2S)-piperidin-2-ylmethanol (460 mg, 3.99 mmol, 1.00 equiv), DIEA (1.29 g, 9.98 mmol, 2.50 equiv) and HATU (1.67 g, 4.39 mmol, 1.10 equiv) in dichloromethane (20 mL). The resulted solution was stirred for 30 min at room temperature. After concentration, the residue was dissolved with 200 mL of EA. Then it was washed with 3 x 20 mL of brine, dried over anhydrous sodium sulfate and concentrated under vacuum to give a residue. The crude was purified by silica gel column eluted with dichloromethane/methanol (10:1). This resulted in 426 mg (46percent, 97percent ee) of [(2S)-l-[(2-methylpyridin-4-yl)carbonyl]- piperidin-2-yl]methanol as yellow oil., 41373-39-1

As the paragraph descriping shows that 41373-39-1 is playing an increasingly important role.

Reference£º
Patent; GLOBAL BLOOD THERAPEUTICS, INC.; LI, Zhe; HARRIS, Jason, R.; DUFU, Kobina, N.; GENG, Xin; SINHA, Uma; (101 pag.)WO2016/160755; (2016); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

188869-05-8, tert-Butyl 3-bromo-4-oxopiperidine-1-carboxylate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

188869-05-8, [0427] A mixture of 5-amino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile (1.5 g, 5.4mmol) and K2C03 (2.24 g, 16.3 mmol) in 50 mL of DMF at 80 DC was stirred under N2 for 45min before tert-butyl3-bromo-4-oxopiperidine-1-carboxylate (4.5 g, 16.3 mmol) was added inone portion. Then the mixture was stirred at 80 DC for 1 hr. After cooling down toRT, 150 mLof water and 150 mL of EA was added. Aqueous phase was further extracted with EA (1 00 mL x 3). The combined organic layers were washed with brine, dried over Na2S04 and concentratedto get crude product which was chromatographed on I5 g of silica gel using DCM/MeOH (40011to 20011) as eluant to afford 850 mg (35%) oftert-butyl3-cyano-2-(4-phenoxyphenyl)-5,6-dihydro -4H -pyrazolo[5′, I’ :2,3 ]imidazo[ 4,5-c ]pyridine-? (8H)-carboxylate as an off-white solid.MS (ESI) m/e [M+ It 455.9.

The synthetic route of 188869-05-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GUO, Yunhang; BEIGENE, LTD.; WANG, Zhiwei; WO2014/173289; (2014); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.138007-24-6,tert-Butyl piperidine-4-carboxylate,as a common compound, the synthetic route is as follows.

Example 87Ethyl 5-chloro-6-(4-{[(4-methylbenzyl)sulfonyl]carbamoyl}piperidin-l-yl)-2-[(2- oxopyrrolidin-l-yl)methyl]nicotinate5 (a) Ethyl 6-[4-(/e^-butoxycarbonyl)piperidin-l-yl]-5-chloro-2-[(2-oxopyrrolidin-l- yl)methyl]nicotinateEthyl 5,6-dichloro-2-[(2-oxopyrrolidin-l-yl)methyl]nicotinate (Example 85(d)) (3.2 g, 9.96 mmol) and tert-bntyl piperidine-4-carboxylate (2.77 g, 15 mmol) were dissolved in DIPEA o (4.4 mL, 24.9 mmol) and iV-methyl-2-pyrrolidone (30 mL), the reaction mixture was heated at 1400C for 1.5 h. Water and DCM were added, the organic phase was washed with 0.5 M HCl, sat. NaHCO3 and water, dried (MgSO4) and concentrated in vacuo. The residue was purified by flash chromatography, DCMiMeOH 100:0 to 90:10 as eluent, to give ethyl 6-[4-(te7Y-butoxycarbonyl)piperidin-l-yl]-5-chloro-2-[(2-oxopyrrolidin-l- 5 yl)methyl]nicotinate. Yield: 3.1 g (67percent).1H-NMR (500 MHz5 CDCl3) delta 1.37 (3H, t), 1.45 (9H, s), 1.80 (2H, m), 1.95 (2H, m), 2.08 (2H, m), 2.40-2.50 (3H, m), 3.00 (2H5 m), 3.49 (2H5 m), 4.04 (2H, m), 4.32 (2H5 q), 4.87 (2H, s), 8.11 (lH, s)., 138007-24-6

As the paragraph descriping shows that 138007-24-6 is playing an increasingly important role.

Reference£º
Patent; ASTRAZENECA AB; WO2008/85119; (2008); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

73874-95-0, tert-Butyl piperidin-4-ylcarbamate is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,73874-95-0

General procedure: To a stirred solution of 2 (0.20 g, 1.00 mmol) in anhydrous DCM(5 mL) was added Et3N (0.42 mL, 3.00 mmol) at room temperature.Then 3a-i (3.96 mmol) was added in small portions at room temperature.The reaction was stirred for 4 h at this temperature and then quenched the reaction with saturated aqueous solution ofNaHCO3. The aqueous layer was extracted with ethyl acetate(3 10 mL). The combined organic layers were dried over anhydrousNa2SO4, filtered, and concentrated. Silica gel flash columnchromatography (EtOAc/hexanes = 1:2) of the residue gave 4a-ias the product. Dissolved 4a-i (0.34 g, 0.97 mmol) in 25 mL TFAat room temperature, the reaction was stirred at room temperature for 10 h. Distilled the TFA under vacuum and then diluted with saturated aqueous solution of NaHCO3. The aqueous layer wasextracted with ethyl acetate (3 10 mL). The combined organiclayers were dried over anhydrous Na2SO4, filtered, and concentrated.Silica gel flash column chromatography (EtOAc/hexanes =1:1) of the residue gave 5a-i as the product.

As the paragraph descriping shows that 73874-95-0 is playing an increasingly important role.

Reference£º
Article; Yue, Hong; Lu, Feng; Shen, Chen; Quan, Jun-Min; Bioorganic Chemistry; vol. 61; (2015); p. 21 – 27;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem